BDBM199027 BDBM199054::BDBM199055::BDBM199056::BDBM199057::US9221832, 122::US9221832, 123::US9221832, 124::US9221832, 125::US9221832, 126::US9221832, 127::US9221832, 91

SMILES CC(C(=O)NC1COc2ncccc12)c1cccc(c1Cl)C(F)(F)F

InChI Key InChIKey=CGZWZKJDTFHJQE-UHFFFAOYSA-N

Data  11 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 11 hits for monomerid = 199027   

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM199027(US9221832, 126 | US9221832, 91 | US9221832, 127 | ...)
Affinity DataIC50: 23nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM199027(US9221832, 126 | US9221832, 91 | US9221832, 127 | ...)
Affinity DataIC50: 24nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM199027(US9221832, 126 | US9221832, 91 | US9221832, 127 | ...)
Affinity DataIC50: 41nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM199027(US9221832, 126 | US9221832, 91 | US9221832, 127 | ...)
Affinity DataIC50: 42nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM199027(US9221832, 126 | US9221832, 91 | US9221832, 127 | ...)
Affinity DataIC50: 45nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM199027(US9221832, 126 | US9221832, 91 | US9221832, 127 | ...)
Affinity DataIC50: 50nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM199027(US9221832, 126 | US9221832, 91 | US9221832, 127 | ...)
Affinity DataIC50: 52nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM199027(US9221832, 126 | US9221832, 91 | US9221832, 127 | ...)
Affinity DataIC50: 156nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM199027(US9221832, 126 | US9221832, 91 | US9221832, 127 | ...)
Affinity DataIC50: 308nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM199027(US9221832, 126 | US9221832, 91 | US9221832, 127 | ...)
Affinity DataIC50: 432nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent

TargetP2X purinoceptor 7(Human)
Actelion Pharmaceuticals

US Patent
LigandPNGBDBM199027(US9221832, 126 | US9221832, 91 | US9221832, 127 | ...)
Affinity DataIC50: 571nMAssay Description:Cell line generation was performed in general according to established molecular cloning protocols. Specifically, RNA was extracted from human whole ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/31/2016
Entry Details
US Patent